ID
45234
Description
Principal Investigator: Dawood Darbar, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Atrial Fibrillation https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000439 The goal of this study was to identify genetic predictors of response to rate control therapy in patients with AF. We conducted a genome-wide association study (GWAS) focusing on subjects with a history of atrial fibrillation. Rate control therapy for AF uses a range of drugs (beta-adrenergic receptor blockers, calcium channel blockers, and digitalis) to depress conduction through the AV node, thereby preventing rapid rates and minimizing symptoms. In large groups of patients, such as the Vanderbilt AF Registry (a clinical and genetic repository with over 1200 patients with ECG-confirmed AF) from which these study subjects were drawn, approximately 5% display failure of aggressive AV nodal-blocking therapy to control ventricular rate. In these patients, interruption of the AV node by ablation and pacemaker implantation are necessary for adequate rate control. Study cases were individuals who underwent AV node ablation and pacemaker implantation after combined therapy with 3 AV nodal-blocking agents was ineffective in rate control. Controls for this study were individuals who met standardized rate-control efficacy criteria (as described in AFFIRM study, Wyse et al, NEJM 2002; PMID: 12466506) for optimal rate control with 2 or fewer AV nodal-blocking agents. Two additional groups were genotyped by RIKEN: An additional group of patients with AF as well as subjects undergoing cardiac surgery in whom AF did not occur post-operatively. All study participants were recruited and treated/evaluated at Vanderbilt University Medical Center. This study was conducted by the Pharmacogenomics of Arrhythmia Therapy subgroup of the Pharmacogenetics Research Network, a nationwide collaboration of scientists studying the genetic contributions to drug response variability. Genotyping was performed by the RIKEN research institute in Japan using the Illumina 610 Quad Beadchip platform.
Link
Keywords
Versions (2)
- 7/21/22 7/21/22 - Simon Heim
- 10/12/22 10/12/22 - Adrian Schulz
Copyright Holder
Dawood Darbar, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA
Uploaded on
October 12, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000439 PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation
Subject ID, gender, age, race, history of hypertension, diabetes mellitus, congestive heart failure, and myocardial infarction, type of atrial fibrillation among participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Sample ID, subject ID, and sample use variables obtained from participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Subject ID, gender, age, race, history of hypertension, diabetes mellitus, congestive heart failure, and myocardial infarction, type of atrial fibrillation among participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
Similar models
Subject ID, gender, age, race, history of hypertension, diabetes mellitus, congestive heart failure, and myocardial infarction, type of atrial fibrillation among participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Sample ID, subject ID, and sample use variables obtained from participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Subject ID, gender, age, race, history of hypertension, diabetes mellitus, congestive heart failure, and myocardial infarction, type of atrial fibrillation among participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
No comments